From: Mental illness and intensification of diabetes medications: an observational cohort study
0-14 days | 15-30 days | 31-180 days | ||||
---|---|---|---|---|---|---|
Parameter† | HR | 95% CI | HR | 95% CI | HR | 95% CI |
MAIN ANALYSIS (Outcome: Intensification) | ||||||
MHC (1 = yes, 0 = no) | 0.99 | 0.96-1.03 | 1.13 | 1.04-1.23 | 1.12 | 1.07-1.18 |
Index HbA1c value 9–9.9‡ | 1.24 | 1.20-1.28 | 1.38 | 1.27-1.50 | 1.36 | 1.29-1.43 |
Index HbA1c value 10–10.9 | 1.32 | 1.26-1.38 | 1.29 | 1.15-1.45 | 1.49 | 1.40-1.59 |
Index HbA1c value 11–11.9 | 1.47 | 1.39-1.56 | 1.68 | 1.46-1.94 | 1.65 | 1.51-1.81 |
Index HbA1c value 12.0+ | 1.57 | 1.47-1.67 | 1.47 | 1.25-1.73 | 1.65 | 1.49-1.82 |
Sex (1 = male, 0 = female) | 0.98 | 0.89-1.08 | 0.92 | 0.73-1.17 | 0.89 | 0.77-1.02 |
Log physical comorbidity index | 1.01 | 0.98-1.04 | 1.03 | 0.95-1.11 | 1.24 | 1.18-1.30 |
Age (per 10 years) | 0.95 | 0.94–0.97 | 0.95 | 0.92-0.99 | 0.93 | 0.91-0.95 |
Any macrovascular comorbidity | 1.01 | 0.98-1.04 | 1.04 | 0.96-1.12 | 1.03 | 0.98-1.08 |
Any microvascular comorbidity | 0.95 | 0.91-0.99 | 0.95 | 0.86-1.05 | 1.15 | 1.08-1.22 |
COMPETING EVENT (CE) ANALYSIS (Outcome: HbA1c value <8.0) | ||||||
MHC (CE) (1 = yes, 0 = no) | 1.16 | 1.08-1.25 | ||||
Index HbA1c value 9–9.9 (CE)‡ | 0.56 | 0.51-0.60 | ||||
Index HbA1c value 10–10.9 (CE) | 0.31 | 0.27-0.36 | ||||
Index HbA1c value 11–11.9 (CE) | 0.28 | 0.22-0.35 | ||||
Index HbA1c value 12.0+ (CE) | 0.24 | 0.18-0.32 | ||||
Sex (CE) (1 = male, 0 = female) | 1.08 | 0.86-1.35 | ||||
Log physical comorbidity index (CE) | 1.29 | 1.21-1.37 | ||||
Age (per 10 years) (CE) | 0.99 | 0.96-1.02 | ||||
Any macrovascular comorbidity (CE) | 0.95 | 0.89-1.01 | ||||
Any microvascular comorbidity (CE) | 1.10 | 1.02-1.20 |